Search Results

Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the Oppenheimer 24th Annual Consumer Growth & E-Commerce Conference, being conducted virtually on Tuesday, June 11th at 1:30 PM EDT.

Perrigo Company plc announced financial results from continuing operations for the fourth quarter and fiscal year ended December 31, 2023.

Perrigo Company plc today announced that it plans to issue its fourth quarter and fiscal year 2023 financial results on Tuesday, February 27th , 2024 and will host a conference call beginning at 8:30 A.M. (EST).

The regulator on Thursday approved Opill, the first oral contraceptive available in the U.S. without a prescription. Perrigo shares rose 6% in response to the news.

The joint committee of external experts voted unanimously in favor of Perrigo, finding that the benefits of allowing non-prescription use of the birth control tablet Opill outweigh its risks.

Perrigo Company plc announced today that the U.S. Food and Drug Administration (FDA) approved Opill ® , a progestin-only daily oral contraceptive, for over-the-counter (OTC) use for all ages.

Perrigo Company plc, a leading provider of Consumer Self-Care Products, announced the appointment of industry professional Patrick Lockwood-Taylor as its new President, Chief Executive Officer and member of the Board of Directors, effective June 30, 2023.

Perrigo Company plc (NYSE: PRGO) (“Perrigo” or the “Company”), a leading provider of Consumer Self-Care Products, today announced financial results from continuing operations for the first quarter ended April 1, 2023.